Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
With
Otsuka America Pharmaceutical
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with a diagnosis of schizophrenia as defined by DSM-IV-TR2 criteria
Out-patients who have been taking Risperidone for minimum 6 weeks who are not optimally controlled and/or experiencing safety/tolerability issues with Risperidone
Men and women, aged 18 - 65 years
You may not be if
Patients who are at risk for committing suicide
Patients with a diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic symptoms, or organic brain syndromes
Meeting DSM-IV-TR criteria for any significant Psychoactive Substance Use Disorder within the 3 months prior to Screening
Treatment-resistant to antipsychotic medication
Clareo Health | A Switch Study of BMS-337039 in Schizophrenic Out-patients
